• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Theralase Technologies Inc (OP:TLTFF)

0.1440 +0.0010 (+0.70%)
Streaming Delayed Price Updated: 10:08 AM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Theralase Technologies Inc

< Previous 1 2 3 Next >
Theralase(R) Extends Warrants
November 12, 2024
Via ACCESSWIRE
Theralase(R) Provides Update on Bladder Cancer Clinical Study
October 07, 2024
Via ACCESSWIRE
Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options
September 24, 2024
Via ACCESSWIRE
Theralase(R) Extends Warrants
September 19, 2024
Via ACCESSWIRE
Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus
September 03, 2024
Via ACCESSWIRE
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
August 28, 2024
Via ACCESSWIRE
Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug
August 21, 2024
Via ACCESSWIRE
Theralase(R) Release’s 2Q2024 Financial Statements
August 12, 2024
Via ACCESSWIRE
Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement
July 08, 2024
Via ACCESSWIRE
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
June 20, 2024
Via ACCESSWIRE
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
June 19, 2024
Via ACCESSWIRE
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
June 18, 2024
Via ACCESSWIRE
Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R)
June 14, 2024
Via ACCESSWIRE
Rutherrin(R) Increases Efficacy of Chemotherapy
June 12, 2024
Via ACCESSWIRE
Ruvidar(TM) Enhances Efficacy of Cancer Drug
June 10, 2024
Via ACCESSWIRE
Theralase(R) Successfully Destroys Lung Cancer
June 06, 2024
Via ACCESSWIRE
Theralase(R) Technology Effective in Virus Inactivation
June 04, 2024
Via ACCESSWIRE
Theralase(R) Release's 1Q2024 Financial Statements
May 30, 2024
Via ACCESSWIRE
Theralase(R) Expands Clinical Team
May 02, 2024
Via ACCESSWIRE
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
April 24, 2024
Via ACCESSWIRE
Theralase(R) Granted Canadian Cancer Vaccine Patent
April 05, 2024
Via ACCESSWIRE
Theralase(R) Release's 4Q2023 Interim Financial Statements
March 27, 2024
Via ACCESSWIRE
Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
March 26, 2024
Via ACCESSWIRE
Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease
February 12, 2024
Via ACCESSWIRE
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
February 08, 2024
Via ACCESSWIRE
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
February 05, 2024
Via ACCESSWIRE
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
January 15, 2024
Via ACCESSWIRE
Theralase Release’s 3Q2023 Interim Financial Statements
November 29, 2023
Via ACCESSWIRE
Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement
November 29, 2023
Via ACCESSWIRE
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
November 17, 2023
Via ACCESSWIRE
< Previous 1 2 3 Next >
Recent Quotes
View More
Symbol Price Change (%)
GOOG  243.71
+6.22 (2.62%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap